Novel Drugs Celebrated as a 'Major Shift' in Combating Drug-Resistant Gonorrhoea
The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the effort against increasingly resistant strains of the bacteria, according to scientists.
An International Challenge
Gonorrhoea infections are escalating worldwide, with figures suggesting over 82 million new cases annually. Particularly high rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to those in 2014.
“The authorization of novel therapies for gonorrhoea is an significant and necessary step in the reality of increasing worldwide cases, the spread of superbugs and the extremely scarce therapeutic options presently on offer.”
Public health authorities are particularly alarmed about the surge in treatment-resistant strains. The WHO has listed it as a "priority pathogen". Recent surveillance found that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.
A Pair of Novel Treatment Options Secure Authorization
Zoliflodacin, alternatively called a brand name, was authorized by the US FDA in recent days for treating gonorrhoea. This infection can lead to major issues, including infertility. Researchers believe that focused deployment of this new drug will help delay the spread of drug resistance.
Gepotidacin, created by the pharmaceutical company GSK, was also approved in close succession. This medication, which is additionally indicated for UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.
An Innovative Approach to Creation
Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to bring it to fruition.
“This authorization signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”
Clinical Trial Data and Global Access
According to findings published in a major medical journal, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This places it at an equal footing with the existing first-line therapy, which involves an injection and a pill. The trial involved nearly 1,000 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.
Through the arrangement of its development partnership, the non-profit has the rights to license and sell the drug in numerous low-income and middle-income countries.
Clinicians treating patients have shared hope. Access to a single-dose, oral treatment of this kind is described as a "game-changer" for gonorrhoea control. This is viewed as vital to lessen the impact of the disease for patients and to stop the proliferation of highly drug-resistant gonorrhoea around the world.
